Sema4: A Patient-Centered Health Intelligence Company

Advancing Healthcare

through data-driven insights
Health Intelligence Company
Centrellis™
Women's Health
Precision Oncology
Robust Research
Robust Research
Health Intelligence Company

A Health Intelligence Company That Puts Patients in the Center

Sema4 is founded on the idea that more information, deeper analysis, and increased engagement will improve the diagnosis, treatment, and prevention of disease.

Learn more
Centrellis™

Centrellis™

Our unique analytics platform, Centrellis, allows us to offer advanced tools to help providers better manage data for patient populations, launch new clinical studies, and easily compare patient outcomes across a healthcare system.

Learn more
Women's Health

Women’s Health

From pregnancy planning to expanded carrier screening, we deploy robust science and cutting-edge tools to give patients more actionable information all along the family journey through advanced genomic testing.

Learn more
Precision Oncology

Precision Oncology

Our family of precision oncology products and services, Sema4 Signal™, provides data-driven care solutions with advanced analytics, digital tools, and exome-based somatic and hereditary cancer genomic tests.

Learn more
Biopharma

Biopharma

Sema4 offers an extensive portfolio of health information solutions, including pre-clinical and clinical trial support, analytics for actionable insights, and advanced sequencing services, to drive informed decision-making across the drug discovery, development, and commercialization lifecycle.

Learn more
Robust Research

Robust Research

Sema4’s accomplished research team includes world leaders in data science, machine learning, network modeling, and genomics. We’ve published more than 150 peer-reviewed papers and remain committed to providing science-driven solutions to the most pressing medical needs.

Learn more

Latest News

October 19th, 2021

Sema4 to Report Third Quarter 2021 Financial Results on Monday, November 15, 2021

Sema4 will release financial results for the third quarter of 2021 after the market close on November 15th.
 Read more
September 13th, 2021

Sema4 Appoints Gustavo Stolovitzky, Computational Biology Expert, as Chief Science Officer

Sema4 appointed Gustavo Stolovitzky, PhD, to the newly established senior leadership position of Chief Science Officer (CSO). Dr. Stolovitzky is a world-renowned expert in computational biology, algorithm development, and disease modeling.
 Read more
September 9th, 2021

Sema4 Launches Sema4 Elements™, a Portfolio of Data Science-Driven Products and Services to Support Reproductive and Generational Health

Sema4 has announced the launch of Sema4 Elements™, a portfolio of information-driven genomic solutions, digital tools for patients and providers, and services that enable providers to treat patients holistically during their reproductive and generational health journey.
 Read more
Featured In
Awards and Recognition
Back to Top
© 2021 Sema4 OpCo, Inc. All rights reserved.